What the study found
The review found that hypodermoclysis, which means giving fluids under the skin, appears to be a feasible and generally safe way to provide hydration in advanced cancer care. The authors also found that evidence for routine clinically assisted hydration remains limited.
Why the authors say this matters
The authors state that clinically assisted hydration near the end of life is controversial because potential benefits and harms are uncertain. They suggest their findings can help individualize decisions based on patient goals and symptom burden.
What the researchers tested
The researchers conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. They included randomized and observational studies in adults with advanced cancer receiving palliative or hospice care, and pooled data on local infusion-site complications and treatment discontinuation when the data were comparable.
What worked and what didn't
Five studies met the inclusion criteria, including cohort studies and randomized trials, and three were suitable for quantitative synthesis. The pooled estimate suggested about 17% of patients experienced local infusion-site complications, but these events were mostly mild and rarely led to stopping treatment. Randomized trials did not consistently show improvements in symptoms or survival with clinically assisted hydration.
What to keep in mind
The evidence base was small, with only five studies included and three used in the pooled analysis. The abstract does not describe other limitations beyond the limited evidence for routine hydration.
Key points
- Hypodermoclysis appeared feasible and generally safe in advanced cancer care.
- About 17% of patients had local infusion-site complications in the pooled analysis.
- The reported complications were mostly mild and rarely caused treatment discontinuation.
- Randomized trials did not consistently show symptom or survival benefits from clinically assisted hydration.
- The authors say decisions should be individualized to patient goals and symptom burden.
Disclosure
- Research title:
- Hypodermoclysis was generally safe in advanced cancer care
- Authors:
- Muhanad Alzahrani, Abdullah Alabbasi, Muhannad Q. Alqirnas, Ziyad Alzahrani, Faris Sultan
- Institutions:
- King Saud bin Abdulaziz University for Health Sciences, King Saud University
- Publication date:
- 2026-03-07
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.